Shree Ganesh Biotech India Ltd Financials
Company Logo

Shree Ganesh Biotech India Ltd Financial Statement

Shree Ganesh Biotech India Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Sep 2024
Revenue2.29
Operating Expense1.96
Net Profit0.32
Net Profit Margin13.97
Earning Per Share0.01
EBIDTA0.32
Effective Tax RateTBA

Shree Ganesh Biotech India Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual20.28
Operating Expenses Annual20.48
Operating Profit Annual0.86
Interest Annual0.00
Depreciation0.00
Net Profit Annual0.62
Tax Annual0.23

Shree Ganesh Biotech India Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning0.48
Cash Flow from Operations10.16
Cash Flow from Investing-10.21
Cash Flow from FinancingTBA
Cash Flow at the End0.43

Shree Ganesh Biotech India Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)4.24
PBIT Margin (%)4.24
PBT Margin (%)4.24
Net PROFIT Margin (%)3.06
Return On Networth / Equity (%)0.99
Return On Networth /Employed (%)1.36
Return On Assets (%)0.98
Total Debt / Equity (X)TBA
Asset Turnover Ratio (%)0.32

Shree Ganesh Biotech India Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual0.00
Total Current Assets Annual3.73
Non Current Assets Annual69.89
Total Shareholders Funds Annual62.98
Total Assets Annual73.62

Shree Ganesh Biotech India Ltd Earning Calls

No Data Availabe

Get Your FAQs Right

As of Nov 5, 2024, Shree Ganesh Biotech India Ltd has a market capitalization of 41.86 Cr. Value Research classifies it as a Micro-Cap company.
Yes, Shree Ganesh Biotech India Ltd is debt-free with a debt-to-equity ratio of 0.00.
In FY 2023 , Shree Ganesh Biotech India Ltd recorded a total revenue of approximately 20.28 Cr marking a significant milestone in the company's financial performance.
Shree Ganesh Biotech India Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately -0.7% and -0.6% annually, respectively..
Shree Ganesh Biotech India Ltd's current PE ratio is 67.52.
Shree Ganesh Biotech India Ltd's ROCE averaged 3.8% from the FY ending March 2022 to 2024, with a median of 4.4%. It peaked at 5.8% in March 2022, reflecting strong capital efficiency over the period..
Shree Ganesh Biotech India Ltd's latest EBIT is Rs. 0.85 Cr, surpassing the average EBIT of Rs. 2.35 Cr over the 5 years..